TACR1 and cancer: In this sense, the knowledge of the roles played by the substance P/neurokinin-1 receptor system in cancer progression has been dramatically increased in recent years and, according to critical findings, the repurposing of aprepitant (a neurokinin-1 receptor antagonist currently used in clinical practice as an antiemetic) as an antitumor agent has been proposed [2,3].